Current and developing therapeutic agents in the treatment of Chagas disease

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 243-253

  Apt, Werner ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Allopurinol; Benznidazole; Chagas disease; Itraconazole; Nifurtimox; Posaconazole; Treatment

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; ALLOPURINOL; AMIODARONE; BENZNIDAZOLE; BUTHIONINE SULFOXIMINE; CYSTEINE PROTEINASE INHIBITOR; ECONAZOLE; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MILTEFOSINE; NATURAL PRODUCT; NIFURTIMOX; PLACEBO; POSACONAZOLE; TRYPANOTHIONE; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

AGRANULOCYTOSIS; ATOPIC DERMATITIS; CHAGAS DISEASE; CONGENITAL INFECTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; ELECTROCARDIOGRAM; ERYTHEMA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GOUT; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PARASITEMIA; POLYMERASE CHAIN REACTION; POLYNEUROPATHY; PREGNANT WOMAN; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; SEROLOGY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TRYPANOSOMA CRUZI; VISCERAL LEISHMANIASIS; VOMITING; WEIGHT REDUCTION; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; PARASITOLOGY; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ANIMALS; CHAGAS DISEASE; CHRONIC DISEASE; HUMANS; NIFURTIMOX; NITROIMIDAZOLES; TIME FACTORS; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS;

EID: 79952059363     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S8338     Document Type: Review

References (70)

1. Apt W. Centenario del descubrimiento de Carlos Chagas (1909-2009). Rev Parasitol Ibero-Latinoam. 2009;68:92-94.
2. Aufderheide A, Salo W, Madden M, et al. A 9000-year record of Chagas disease. Proc Natl Acad Sci U S A. 2004;101:2034-2039.
3. Pinto Dias J. Tratamiento etiológico de la enfermedad de Chagas. En XII Reunión de la Comisión Intergubernamental del Cono Sur para la eliminación de Triatoma infestans y la interrupción de la transmisión transfusional de la Tripanosomiasis Americana (INCOST/ Chagas). Washington, DC: Pan American Health Organization; 2004: 129-134.
4. Coura R. Chagas disease: clinical and therapeutic features. Enferm Emerg. 2005;8:18-24.
5. Steverding D, Tyler K. Novel antitrypanosomal agents. Expert Opin Investig Drugs. 2005;14:939-955.
6. Andrade Z, Andrade S. Patología Da Doença de Chagas. In Brener Z, Andrade Z, Barral-Neto M, editors. En Trypanosoma cruzi e doença de Chagas 2da. Edición. Río de Janeiro, Brazil: Guanabara Koogan; 2000:201-230.
7. Teixeira A, Nascimento R, Sturn N. Evolution and pathology in Chagas disease -a review. Mem Inst Oswaldo Cruz. 2006;101:463-491.
8. Faundez M, Pino L, Letelier P, et al. Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi. Antimicrob Agents Chemother. 2005;49:126-130.
9. Cazzulo J. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas disease. Curr Top Med Chem. 2002;2: 1261-1271.
10. Urbina J. New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis). Expert Opin Ther Pat. 2003;13: 661-669.
11. Garzoni L, Waghabi M, Baptista M, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas disease. Int J Antimicrob Agents. 2004;23:286-290.
12. Hucke O, Gelb M, Verlinde C, et al. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem. 2005;48:5415-5418.
13. Lepesheva G, Zaitseva N, Nes W, et al. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B ́ helix defines substrate preferences of sterol 14 alpha-demethylase. J Biol Chem. 2006;281: 3577-3585.
14. Avila J, Avila A. Trypanosoma cruzi allopurinol in the treatment of mice with experimental acute Chagas disease. Exp Parasitol. 1981;51: 204-208.
15. Avila J, Avila A, Muñoz E, et al. Trypanosoma cruzi: 4-aminopyrazolopyrimidine in the treatment of experimental Chagas disease. Exp Parasitol. 1983;56:236-240.
16. Apt W, Aguilera X, Arribada A, et al. Treatment of chronic Chagas disease with itraconazole and allopurinol. Am J Trop Med and Hyg. 1998;59:133-138.
17. Apt W, Arribada A, Zulantay I, et al. Itraconazole an Allopurinol in the treatment of chronic American tripanosomiasis: the results of clinical and parasitological examinations 11 years post treatment. Ann Trop Med Parasitol. 2005;99:733-741.
18. Tomimori-Yamashita J, Deps P, Almeida D, et al. Cutaneous manifestation of Chagas disease after heart transplantation: successful treatment with allopurinol. Br J Dermatol. 1997;4:626-630.
19. Urbina J. Chemotherapy of Chagas disease. Curr Pharm Des. 2002;8:287-295.
20. McCabe E, Remington J, Aranjo F. In vitro and in vivo effect of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg. 1986;35: 280-284.
21. Zulantay I, Apt W, Gil LC, et al. The PCR-based detection of Trypanosoma cruzi in the faeces of Triatoma infestans fed on patients with chronic American trypanosomiasis gives higher sensitivity and a quicker result than routine xenodiagnosis. Ann Trop Med Parasitol. 2007;101:673-679.
22. Skies D, Vazquez J, Anstead G, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44:607-614.
23. Benaim G, Sanders JM, Garcia-Marchán Y, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem. 2009;49:892-999.
24. Pinazo M, Espinosa G, Gállego M. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg. 2010;82:583-587.
25. Morello A, Lipchenca I, Cassels B, et al. Trypanocidad effect of boldine and related alkaloids up on several strains of Trypanosoma cruzi. Comp Biochem Physiol. 1994;90:1-12.
26. Tempone A, Borborema S, de Andrade H Jr, et al. Antiprotozoal activity of Brazilian plant extracts from isoquinoline alkaloid-producing families. Phytomedicine. 2005;12:382-390.
27. Rubio J, Calderon J, Flores A, et al. Trypanocidad activity of oleoresin and terpenoids isolated from Pinus oocarpa. Naturforsch. 2005;60: 711-716.
28. Uchiyama N, Kabututu Z, Kubata B, et al. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme. Antimicrob Agents Chemother. 2005;49:5123-5126.
29. Leite J, Oliveira A, Lombardi J, et al. Trypanocidad activity of triterpenes from Arrabidaea triplinervia and derivatives. Biol Pharm Bull. 2006;29:2307-2309.
30. de Oliveira C, Santana L, Carmona A, et al. Structure of cruzipain/ cruzain inhibitors isolated from Bauhinia bauhinioides seeds. Biol Chem. 2001;382:847-852.
31. Apt W, Heitman I, Jercic MI, et al. Guía clínicas para la enfermedad de Chagas. Parte II Enfermedad de Chagas en el adulto. Parte IV Tratamiento. Rev Chilena Infectol. 2008;25:194-199 and 379-389.
32. Rassi A, Rassi A Jr, Rassi S. Cardiopatía crónica: arritmias. In Pinto Dias J, Coura J, editors. Doença de Chagas. Um manual para o clinico general. Río de Janeiro, Brazil: Fio Cruz; 1997:201-222.
33. Prata A. Abordagem general do paciente chagasico. In Pinto Dias J, Coura, editors. Clinica e terapeutica do doença de Chagas. Um manual práctico para o clinico general. Río de Janeiro: Fio Cruz; 1997: 115-126.
34. Pinto Dias J. The treatment of Chagas Disease (South American tripanosomiasis). Ann Int Med. 2006;144:772-774.
35. Maya J, Cassels B, Iturriaga-Vasquez P, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol. 2006;146:601-620.
36. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment of Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009;7:157-163.
37. Acosta A, Santos-Buch C. Autoimmune myocarditis induced by Trypanosoma cruzi. Lab Invest. 1985;71:1255-1261.
38. Kierszenbaum F. Chagas disease and the autoimmunity hypothesis. Clin Microbiol Rev. 1999;12:210-223.
39. Andrade S, Pimentel A, de Souza M, et al. Interstitial dendritic cells of the heart harbor Trypanosoma cruzi antigens in experimentally infected dogs: importance for the pathogenesis of chagasic myocarditis. Am J Trop Med Hyg. 2000;63:64-70.
40. Cunha-Neto E, Duranti M, Gruber A, et al. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci U S A. 1995;92:3541-3545.
41. Burgos J, Begher S, Silva H, et al. Molecular identif ication of Trypanosoma cruzi tropism for central nervous system in Chagas reactivation due to AIDS. Am J Trop Med Hyg. 2008;78:294-297.
42. Vago A, Andrade L, Leite A, et al. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas disease: differential distribution of genetic types into diverse organs. Am J Pathol. 2000;156:1805-1809.
43. Marin-Neto J, Cunha-Neto E, Maciel B, et al. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115:1109-1123.
44. Zhang L, Tarleton R. Parasite persistence correlates with disease severity and localization in chronic Chagas disease. J Infect Dis. 1999;180:480-486.
45. Schijman A, Vigliano C, Viotti R, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic Chagas heart disease. Am J Trop Med Hyg. 2004;70:210-220.
46. Benvenuti L, Roggerio A, Freitas H, et al. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann Trop Med Parasitol. 2008;102:481-487.
47. Viotti R, Vigliano C, Armenti H, et al. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994;127:151-162.
48. Rodriguez Coura J, de Castro S. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002;97:3-24.
49. Garcia S, Ramos C, Senra J, et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob Agents Chemother. 2005;49:1521-1528.
50. Muratore C, Baranchuk A. Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy. Vasc Health Risk Manag. 2010;6:593-601.
51. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724-734.
52. Sosa-Estani S, Segura E. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis. 2006;19:583-587.
53. Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected evidence by evidence-based medicine. Expert Rev Anti Infect Ther. 2007;5:717-726.
54. OPS-OMS. Tratamiento etiológico de la enfermedad de Chagas. Conclusiones de una consulta técnica. Río de Janeiro: Inst Oswaldo Cruz; 1998.
55. Marin-Neto J, Rassi A Jr, Morillo C, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas cardiomyopathy: the Benznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J. 2008;156: 37-43.
56. Marin-Neto J, Rassi A Jr, Avezum A Jr, et al. Benefit trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009;1:319-324.
57. Grippo V, Mahler E, Elias F, et al. The heavy chain variable segment gene repertoire in chronic Chagas heart disease. J Immunol. 2009;183: 8015-8025.
58. Cerisola J. Evolución serológica de pacientes con enfermedad de Chagas aguda tratados con Bay 2502. Bol Chil Parasitol. 1969;24:54-59.
59. Cançado R. Tratamiento etiológico do doença de Chagas pelo benznidazol. Capitulo 19. Libro Trypanosoma cruzi e doença de Chagas. Brener Z, Andrade Z, Barral-Neto M, editors. Río de Janeiro, Brazil: Guanabara Koogan; 2000:389-405.
60. Virreira M, Torrico F, Truyens C, et al. Comparison of polymerase chain reaction methods for reliable and easy detection of congenital Trypanosoma cruzi infection. Am J Trop Med Hyg. 2003;68:574-582.
61. Sánchez O, Mora M, Basombrio M. High prevalence of congenital Trypanosoma cruzi infection and clustering in Salta, Argentina. Pediatrics. 2005;115:668-672.
62. Russomando G, Almiron M, Candra N, et al. Implementation and evaluation of a locally sustainable system of prenatal screening that allows the detection of cases of congenital transmission of Chagas disease in endemic zone of Paraguay. Rev Soc Bras Med Trop. 2005;38:49-54.
63. WHO. Control of Chagas disease. WHO Technical Report Series N-905, Geneva, Switzerland: WHO; 2002.
64. Bustamante J, Bixby L, Tarleton R. Drug induced cure drives conversion to a stable and protective CD8T central memory response in chronic Chagas disease. Nat Med. 2008;14:542-550.
65. Duffy T, Bisio M, Altcheh J, et al. Accurate real-time PCR strategy for monitoring bloodstream parasites loads in Chagas disease patients. PLoS Negl Trop Dis. 2009;3:419-429.
66. Britto C. Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem Inst Oswaldo Cruz. 2009;104:122-135
67. Solari A, Muñoz S, Venegas J, et al. Characterization of Chilean, Bolivian and Argentinian Trypanosoma cruzi populations by restrictive endonuclease and isoenzime analysis. Exp Parasitol. 1992;75:187-195.
68. Andrade S, Magalhaes J, Pontes A. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull World Health Organ. 1985;63: 721-726.
69. Filardi L, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81:755-759.
70. Coronado X, Zulantay I, Rozas M, et al. Dissimilar distribution of Trypanosoma cruzi clones in humans alter chemotherapy with allopurinol and itraconazole. J Antimicrob Chemother. 2006;58:216-219.